Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Reports Second Quarter 2021 Financial Results
Corporate and Regulatory Highlights U.S. Commercial Launch of AZSTARYS™ Initiated on July 21, 2021 Serdexmethylphenidate (SDX) Classified as a Schedule IV Controlled Substance by the DEA Announced Orange Book Listing for Six Patents Covering SDX and Confirmation of NCE Status KemPharm Added to
Toggle Summary KemPharm to Report Second Quarter 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021 , 4:30 p.m. ET CELEBRATION, Fla. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
CELEBRATION, Fla. , July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for the treatment of attention
Toggle Summary KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
CELEBRATION, Fla. , June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable
Toggle Summary KemPharm Issues Letter to Shareholders
CELEBRATION, Fla. , June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders
Toggle Summary KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021
CELEBRATION, Fla. , June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000 ®  Index and the Russell 2000 ®  Index in
Toggle Summary KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences
CELEBRATION, Fla. , June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and Chief Executive Officer of KemPharm , will
Toggle Summary KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status
SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™ CELEBRATION, Fla. , May 26, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Reports First Quarter 2021 Financial Results
Corporate and Regulatory Highlights AZSTARYS TM NDA approved by the FDA on March 2, 2021 Announced amendment to Licensing Agreement with Gurnet Point Capital affiliate following FDA approval of AZSTARYS Received FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use
Toggle Summary KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA CELEBRATION, Fla. , May 07, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the